The biomarker profiling project is expected to enable a better understanding of how lifestyle, environment, and genetics combine to cause diseases.
Diagnostic WGS will be centralized and performed at the same Genomics England facility used in the 100,000 Genomes Project.
Nova Satra said it will use the EpiSwitch technology to develop and commercialize non-invasive breast cancer testing across 13 territories in Asia.
Numares will use its technology to advance work by Oxford researchers to create a noninvasive test to better diagnose MS.
The meta-analysis further suggested that efforts to screen and treat people at risk of developing diabetes might not be effective.
The test is based on MDNA's Mitomic technology, which enables the isolation of mitochondrial DNA in circulation that may be used as biomarkers.